Free Trial
OTCMKTS:RGIN

Regenicin (RGIN) Stock Price, News & Analysis

Regenicin logo

About Regenicin Stock (OTCMKTS:RGIN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
17,300 shs
Market Capitalization
$17,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

Receive RGIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter.

RGIN Stock News Headlines

History
Regenicin, Inc. (RGIN)
Recession Fears Mounting? 2 AI Stocks to Watch Now
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
History of Walmart: Timeline and Facts
See More Headlines

RGIN Stock Analysis - Frequently Asked Questions

Regenicin, Inc. (OTCMKTS:RGIN) issued its quarterly earnings results on Wednesday, August, 19th. The company reported $0.00 EPS for the quarter.

Shares of RGIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regenicin investors own include Energous (WATT), Cheniere Energy (LNG), Vital Therapies (VTL), Xerox (XRX), Allergan (AGN) and Leafbuyer Technologies (LBUY).

Company Calendar

Last Earnings
8/19/2020
Today
6/03/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:RGIN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$17,000.00
Optionable
Not Optionable
Beta
-18.91
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (OTCMKTS:RGIN) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners